Zelira Therapeutics Limited

As of June 30, 2025, Zelira Therapeutics Limited has 11.90M shares outstanding.

These figures are as of June 30, 2025. The price-to-sales ratio is 7,702.11, and the price-to-book ratio stands at -1.17.

These figures are as of June 30, 2025. The EV/Sales ratio of 11,494.86 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Zelira Therapeutics Limited trades at an EV/FCF ratio of 18.52, comparing the total takeover cost of the business to the cash it actually generates for all capital providers.

As of June 30, 2025, Zelira Therapeutics Limited maintains a current ratio of 0.11, meaning it holds 0.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -49.91, indicating conservative leverage, while an interest coverage ratio of -9.35 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2025. Return on assets (ROA) is negative at -111.90, reflecting losses generated across the asset base. Inventory turnover of 0.01 indicates how many times Zelira Therapeutics Limited sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2025, Zelira Therapeutics Limited posted a gross margin of -1,245.43, reflecting its pricing power and cost economics. The operating margin of -580,710.82 and net profit margin of -553,029.27 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2025. Total shareholder yield is negative at -60.93, meaning Zelira Therapeutics Limited raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Zelira Therapeutics Limited's most recent stock split took place on April 14, 2022 with a 175:1 split ratio.

As of June 30, 2025, Zelira Therapeutics Limited has an Altman Z-Score of -175.70, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.